针对中东呼吸综合征冠状病毒的全人源单克隆抗体的研究进展

Research progress on human neutralizing monoclonal antibodies against Middle East respiratory syndrome coronavirus

中东呼吸综合征冠状病毒(MERS-CoV)是继严重急性呼吸综合征冠状病毒(SARS-CoV)之后发现的一种能引起人类严重急性呼吸道疾病、具有高致死率的新型冠状病毒。该病毒已从主要流行的中东地区逐渐蔓延至多个国家,具有全球流行的潜在趋势,引起世界各国的极大关注。本文对近期抗MERS-CoV人中和单克隆抗体的研究进展进行总结,描述这些抗体的作用机制,分析其防治MERS的潜在能力,并探讨抗体类抗病毒药物用于新发传染病防治的应用前景和发展方向。

Middle East respiratory syndrome coronavirus （MERS-CoV） is a novel eoronavirus, which can cause severe acute respiratory disease with a high mortality rate. Currently, MERS-CoV has spread from the main epidemic area, the Middle East Region, to many other countries including the United States of America, Republic of Korea and China. MERS-CoV has raised global public health concerns regarding the current situation and future evolution. This review will mainly summarize the recent progress on developing human neutralizing monoclonal antibodies （mAbs） against MERS-CoV, describe the action mechanisms, and discuss their potential for prophylaxis and treatment of MERS. The future strategies for the rapid development of antibody-based antiviral options to combat emerging viruses and diseases in an outbreak setting are also discussed.